Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Myeloid Leukemia
58%
Diffuse Large B-cell Lymphoma (DLBCL)
44%
Relapsed or Refractory
37%
Myelodysplastic Syndrome
34%
Overall Survival
33%
Confidence Interval
26%
Rituximab
26%
Lymphoma Patients
25%
Decitabine
24%
Mantle Cell Lymphoma
24%
Phase II Study
23%
Granulocyte Colony-stimulating Factor (G-CSF)
23%
Plerixafor
22%
Natural Killer Cells
21%
Complete Remission
20%
Progression-free Survival
19%
Autologous Transplantation
19%
Follicular Lymphoma
18%
Chemotherapy
18%
Hodgkin Lymphoma
17%
Cytarabine
17%
Relapsed Lymphoma
17%
Graft-versus-host Disease (GvHD)
16%
Azacitidine
16%
Lenalidomide
16%
Leukemia
15%
Lymphoma
15%
Older Patients
15%
Phase I Study
15%
Memory-like
13%
Relapsed or Refractory Acute Myeloid Leukemia
13%
Classical Hodgkin Lymphoma
13%
Hazard Ratio
13%
Stem Cells
12%
Overall Response Rate
12%
Interleukin-15 (IL-15)
11%
Stem Cell Mobilization
11%
Hematopoietic Cell Transplantation
11%
Unrelated Donor
11%
Leukemia Patients
11%
Peripheral T-cell Lymphoma
10%
Conditioning Regimen
10%
Cyclophosphamide
9%
Myeloablative Conditioning
9%
Clinical Trials
9%
High Risk
9%
Reduced-intensity Conditioning
9%
Hypomethylating Agents
9%
Chronic Lymphocytic Leukemia
9%
Medicine and Dentistry
Hematopoietic Cell
54%
Acute Myeloid Leukemia
47%
Cell Transplantation
47%
Diffuse Large B-Cell Lymphoma
35%
Transplantation
34%
Overall Survival
34%
Neoplasm
21%
Mantle Cell Lymphoma
21%
Plerixafor
21%
Hodgkin's Lymphoma
20%
Rituximab
20%
Myelodysplastic Syndrome
19%
Natural Killer Cell
18%
Decitabine
16%
Progression Free Survival
16%
Classical Hodgkin Lymphoma
16%
Diseases
14%
Azacitidine
14%
Stem Cell Transplant
13%
Granulocyte Colony Stimulating Factor
13%
Autotransplantation
12%
Leukemia
12%
Allogeneic Stem Cell Transplantation
12%
Autologous Stem Cell Transplantation
11%
Stem Cell
11%
Hematopoietic Stem Cell Transplantation
11%
Lenalidomide
10%
Follicular Lymphoma
10%
Cytarabine
10%
Hazard Ratio
10%
Clinical Trial
10%
Graft Versus Host Reaction
9%
Cell Therapy
9%
Positron Emission Tomography-Computed Tomography
8%
Bendamustine
8%
Chemokine Receptor CXCR4 Antagonist
8%
Stem Cell Mobilization
7%
Conditioning
7%
T Cell
7%
Reduced Intensity Conditioning
7%
Polyethylene Terephthalate
7%
Allograft
7%
Myeloablative Conditioning
7%
Hypomethylating Agent
6%
Non-Hodgkin Lymphoma
6%
Peripheral T-Cell Lymphoma
6%
T-Cell Lymphoma
6%
Cancer
6%
Maintenance Therapy
6%
Lymphoma Cell
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
47%
Myelodysplastic Syndrome
35%
Remission
26%
Decitabine
22%
Diffuse Large B Cell Lymphoma
18%
Plerixafor
18%
Rituximab
18%
Azacitidine
16%
Overall Survival
16%
Lenalidomide
16%
Cytarabine
15%
Progression Free Survival
13%
Granulocyte Colony Stimulating Factor
12%
Neoplasm
12%
Diseases
10%
Follicular Lymphoma
9%
Mantle Cell Lymphoma
9%
Graft Versus Host Reaction
9%
Chemotherapy
9%
Bendamustine
8%
Polyethylene Terephthalate
8%
Chronic Lymphatic Leukemia
8%
Belinostat
8%
Cyclophosphamide
8%
Pharmacokinetics
7%
Maximum Tolerated Dose
7%
Adverse Event
7%
Clinical Trial
7%
Tolerability
6%
Multiple Myeloma
6%
Nonhodgkin Lymphoma
6%
Fludarabine
6%
Classical Hodgkin Lymphoma
5%
Peripheral T Cell Lymphoma
5%
Chemokine Receptor CXCR4 Antagonist
5%
Clofarabine
5%